UBS Maintains Buy on Chemours, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Joshua Spector maintains a Buy rating on Chemours (NYSE:CC) and raises the price target from $41 to $43.
June 13, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Joshua Spector maintains a Buy rating on Chemours and raises the price target from $41 to $43.
The news of UBS maintaining a Buy rating on Chemours and raising the price target from $41 to $43 indicates a positive outlook for the company. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100